Cannabidiol Attenuates Pulmonary Arterial Hypertension by Normalizing the Mitochondrial Function in Vascular Smooth Muscle Cells
X. Lu, J. Zhang, H. Liu, W. Ma, X. Tan, S. Wang, Y. Leo, F. Ren, X. Li, X. Li
Abstract
Pulmonary artery hypertension (PAH) is a chronic disease associated with enhanced proliferation of pulmonary artery smooth muscle cells (PASMCs) and dysfunctional mitochondria, which was with limited therapeutic options. It has been proved that cannabidiol (CBD) had antioxidant effects in many cardiovascular diseases, whereas the efficacy of CBD in PAH is unknown. To defined the effect of CBD in PAH, we explored the functions of CBD in both PASMCs proliferation test in vitro, and preventive and therapeutic PAH rodent models in vivo. The roles of CBD in mitochondria function and the oxidant stress were assessed in human PASMCs and PAH mice. We found that CBD significantly inhibited hyperproliferation of hypoxia-induced PASMCs, and intragastrically administered CBD could reverse the pathological changes in both Sugen-hypoxia and MCT-induced PAH mice models. Mechanical analysis demonstrated that CBD alleviated PAH by recovering mitochondrial energy metabolism, normalizing the hypoxia-induced oxidant stress, inhibiting abnormal glycolysis and lactate accumulation in cannabinoids receptors-independent manner. Thus, CBD could be a potential drug for PAH. Graphical Abstracts O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=88 SRC="FIGDIR/small/364547v2_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@161d73corg.highwire.dtl.DTLVardef@79a5e0org.highwire.dtl.DTLVardef@791b86org.highwire.dtl.DTLVardef@fdfdbb_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Therapeutic Potential of 20E in Pulmonary Arterial Hypertension: Involvement of Mas Receptor and PI3K/Akt Pathway
Tong Lu, Weiwei Jia, … Lin Yan·bioRxiv·Apr 3, 2025
- Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension
Chanil Valasarajan, Golnaz Hesami, … Soni Savai Pullamsetti·bioRxiv·Oct 27, 2024
- The hepcidin-ferroportin axis influences mitochondrial function, proliferation, and migration in pulmonary artery endothelial and smooth muscle cells
T. Issitt, Q. Toe, … G. J. Quinlan·bioRxiv·Oct 9, 2023
- Interrogation of the glycolytic axis in pulmonary arterial hypertension models and how modifying these can lead to potential therapeutic options.
Rachel Sutcliffe, Iona Cuthbertson, … Elaine Soon·bioRxiv·Jan 14, 2026
- RAB7 deficiency impairs pulmonary artery endothelial function and promotes pulmonary hypertension
B. Piper, S. Bogamuwa, … L. Farkas·Journal of Clinical InvestigationPeer-reviewed·Feb 1, 2024
- CD133+ progenitor cells promote pulmonary hypertension through CXCR4 signaling
Zhiqing Wang, Dan Yi, … Zhiyu Dai·bioRxiv·Aug 2, 2026